Abstract
A pharmaceutical company is proceeding with clinical testing of a new compound that could make it easier for diabetic patients to maintain good control of blood-sugar levels. The compound, a peptide called amylin, appears to lessen wild fluctuations in blood-glucose levels by slowing the rate of gastric emptying and moderating the amount of postprandial glucose. Fran Lowry interviewed the researcher who discovered the peptide.
- Copyright © 1996 by Canadian Medical Association